Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Unusually active option classes on open April 6th » 09:40
04/06/20
04/06
09:40
04/06/20
09:40
MNK

Mallinckrodt

$1.70 /

+ (+0.00%)

, PENN

Penn National

$9.75 /

+ (+0.00%)

, LUV

Southwest

$30.53 /

+ (+0.00%)

, DAL

Delta Air Lines

$22.48 /

+ (+0.00%)

, USO

United States Oil Fund

$5.91 /

+0.005 (+0.08%)

, ACB

Aurora Cannabis

$0.80 /

+ (+0.00%)

, M

Macy's

$4.81 /

+ (+0.00%)

, MSFT

Microsoft

$153.92 /

+ (+0.00%)

, TEVA

Teva

$8.40 /

+ (+0.00%)

, GILD

Gilead

$78.22 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Mallinckrodt (MNK), Penn National (PENN), Southwest (LUV), Delta Air Lines (DAL), United States Oil Fund (USO), Aurora Cannabis (ACB), Macy's (M), Microsoft (MSFT), Teva (TEVA), and Gilead (GILD).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Teva upgraded to Buy from Neutral at UBS » 06:28
04/06/20
04/06
06:28
04/06/20
06:28
TEVA

Teva

/

+

UBS analyst Kevin…

UBS analyst Kevin Caliendo upgraded Teva to Buy from Neutral with a price target of $12, down from $14. The analyst notes that the stock has underperformed a market that is "overly discounting" its earnings, credit risk and business disruption. While he sees some risk to Teva's new product launches, Caliendo sees these "broadly balanced" by opportunities such as the accelerated respiratory franchise volume. The analyst adds that his out year estimates a lower on potentially longer growth path for new launches, but his near-term forecast for Teva's EBITDA is unchanged.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Friday
Conference/Events
Roth Capital biotech analyst to hold an analyst/industry conference call » 15:21
04/03/20
04/03
15:21
04/03/20
15:21
AMRN

Amarin

$4.68 /

-0.55 (-10.53%)

, MTNB

Matinas BioPharma

$0.53 /

-0.04 (-7.02%)

Biotechnology Analyst…

Biotechnology Analyst Rahimi, along with Dr. Kevin Maki, discuss how fatty acids and Omega-3s are all not the same on an Analyst/Industry conference call to be held on April 9 at 2 pm.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 10:25
04/03/20
04/03
10:25
04/03/20
10:25
GILD

Gilead

$78.61 /

+1.65 (+2.14%)

, MYL

Mylan

$14.25 /

+0.34 (+2.44%)

, TEVA

Teva

$8.55 /

+0.43 (+5.30%)

, AMRX

Amneal Pharmaceuticals

$3.02 /

-0.025 (-0.82%)

, ABBV

AbbVie

$74.23 /

-0.895 (-1.19%)

, REGN

Regeneron

$498.01 /

-0.74 (-0.15%)

, ALNY

Alnylam

$102.80 /

-1.58 (-1.51%)

, MRNA

Moderna

$33.88 /

+0.68 (+2.05%)

, INO

Inovio

$7.31 /

-0.19 (-2.53%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 04:55
04/03/20
04/03
04:55
04/03/20
04:55
GILD

Gilead

$76.96 /

+4.41 (+6.08%)

, MYL

Mylan

$13.91 /

-0.34 (-2.39%)

, TEVA

Teva

$8.12 /

-0.35 (-4.13%)

, AMRX

Amneal Pharmaceuticals

$3.05 /

+0.015 (+0.50%)

, ABBV

AbbVie

$75.13 /

+1.655 (+2.25%)

, REGN

Regeneron

$498.75 /

+2.08 (+0.42%)

, ALNY

Alnylam

$104.38 /

-0.13 (-0.12%)

, MRNA

Moderna

$33.20 /

+3.52 (+11.86%)

, INO

Inovio

$7.50 /

-0.19 (-2.47%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Conference/Events
Piper Sandler biopharma analysts to hold an analyst/industry conference call » 09:47
04/02/20
04/02
09:47
04/02/20
09:47
GILD

Gilead

$72.64 /

+0.09 (+0.12%)

, MYL

Mylan

$14.00 /

-0.25 (-1.75%)

, TEVA

Teva

$8.34 /

-0.135 (-1.59%)

, AMRX

Amneal Pharmaceuticals

$3.07 /

+0.04 (+1.32%)

, ABBV

AbbVie

$73.07 /

-0.4 (-0.54%)

, REGN

Regeneron

$493.41 /

-3.26 (-0.66%)

, ALNY

Alnylam

$105.05 /

+0.54 (+0.52%)

, MRNA

Moderna

$30.60 /

+0.92 (+3.10%)

, INO

Inovio

$7.44 /

-0.25 (-3.25%)

Biopharma Analysts…

Biopharma Analysts Amsellem and Raymond, along with a physician based at the University of Pisa Hospital in Pisa, Italy, who has managed over 100 COVID-19 patients and provides his perspective where New York area could be in 2-3 weeks, on an Analyst/Industry conference call to be held on April 3 at 11 am.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Unusually active option classes on open April 2nd » 09:40
04/02/20
04/02
09:40
04/02/20
09:40
AMRN

Amarin

$4.97 /

+ (+0.00%)

, AUY

Yamana Gold

$2.92 /

+ (+0.00%)

, JD

JD.com

$40.92 /

+ (+0.00%)

, IWM

iShares Trust Russell 2000 Index Fund

$106.58 /

-0.07 (-0.07%)

, SBUX

Starbucks

$62.63 /

+ (+0.00%)

, USO

United States Oil Fund

$4.38 /

+0.01 (+0.23%)

Unusual total active…

Unusual total active option classes on open include: Amarin (AMRN), Yamana Gold (AUY), JD.com (JD), iShares Russell 2000 ETF (IWM), Starbucks (SBUX), and United States Oil Fund (USO).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Menlo Therapeutics announces settlement to conclude Finacea Foam litigation » 08:07
04/02/20
04/02
08:07
04/02/20
08:07
MNLO

Menlo Therapeutics

$2.39 /

-0.27 (-10.15%)

, FOMX

Foamix

$0.00 /

+ (+0.00%)

, TEVA

Teva

$8.47 /

-0.51 (-5.68%)

, PRGO

Perrigo

$45.00 /

-3.13 (-6.50%)

Menlo Therapeutics (MNLO)…

Menlo Therapeutics (MNLO) announced that its wholly-owned subsidiary, Foamix Pharmaceuticals Ltd. (FOMX) has entered into a settlement and license agreement to resolve the remaining pending patent litigation involving Finacea Foam. Details of the settlement agreement are confidential, and the settlement agreement is subject to the review of the Federal Trade Commission and the U.S. Department of Justice. Foamix is the owner of patents that have been licensed to LEO Pharma A/S to market Finacea Foam, a topical prescription medicine used to treat the inflammatory papules and pustules of mild to moderate rosacea. This settlement concludes the litigation relating to Finacea Foam and comes after the settlements in October 2019 with an affiliate of Teva Pharmaceutical Industries (TEVA) and in April 2019 with affiliates of Perrigo Company (PRGO).

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Cowen suggests company sale and CVR 'makes the most sense' for Amarin » 06:44
04/02/20
04/02
06:44
04/02/20
06:44
AMRN

Amarin

$4.97 /

+0.975 (+24.44%)

Cowen analyst Ken…

Cowen analyst Ken Cacciatore said he believes a sale of the company and a CVR, or contingent value right, to ensure optionality of a possible Vascepa U.S. patent appeal reversal "simply makes the most sense" at this point for Amarin given its recent U.S. patent case loss and the upcoming European commercial decision. He sees the EU opportunity as one that could reach $1.5B-$2B and is protected to 2033, adding that a potential global commercial player could also quickly leverage Vascepa in the U.S. over the next 12 months before the appeal is decided. Under "almost all scenarios," he believes a $5 trading level for Amarin shares provides an "exceptionally compelling opportunity," concluded Cacciatore, who has an Outperform rating and $8 price target on the stock.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Jefferies boosts Amarin target to $6 after speaking with patent lawyer » 06:17
04/02/20
04/02
06:17
04/02/20
06:17
AMRN

Amarin

$4.97 /

+0.975 (+24.44%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee raised the firm's price target on Amarin to $6 from $4 and keeps a Hold rating on the shares after hosting a call with a patent lawyer. The stock closed Wednesday up 24.5%, or 98c, to $4.98 as headlines from the call hit news services. Per a patent lawyer expert, there was a potential procedural error in the Vascepa patent ruling, Yee tells investors in a research note. As such, the lawyer believes Amarin has around a 50% chance of winning an appeal and a good likelihood of a preliminary injunction in a few weeks, adds the analyst. However, Yee points out an appeal could take 12 months and won't be expedited. A "call option" on an appeal win makes Amarin shares "interesting," but it will take time to next year's ruling, concludes Yee.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.